SCHEMBL16619150

SCHEMBL16619150

CC(C)(C)OC(=O)N1C(Cc2ccc(C(=O)O)cc2)CCC1C(O)c1ccc(OC(F)F)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
PDE4D Q08499 1/20 0.35
ALDH1A1 P00352 4/20 0.34
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
MRGPRX4 Q96LA9 1/20 0.34
ACACB O00763 1/20 0.34
CETP P11597 2/20 0.33
TSHR P16473 1/20 0.33
MDM2 Q00987 1/20 0.33
ALKBH1 Q13686 1/20 0.33
CPT1A P50416 1/20 0.33
CPT1B Q92523 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
PTGER4 P35408 1/20 0.33
CACNA1H O95180 1/20 0.33
HTT P42858 1/20 0.32
ATM Q13315 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16619147 1.00 MEN1 (0.36) MEN1KMT2APDE4DALDH1A1RXRA
SCHEMBL16629712 0.91 HDAC1 (0.38) MEN1KMT2APDE4DALDH1A1ACACB
SCHEMBL16619212 0.89 CETP (0.37) MEN1KMT2ACETP
SCHEMBL1509715 0.89 CETP (0.37) MEN1KMT2ACETP
SCHEMBL1509714 0.89 CETP (0.37) MEN1KMT2ACETP
SCHEMBL9933316 0.89 CETP (0.37) MEN1KMT2ACETP
SCHEMBL16629753 0.83 PDE5A (0.38) CETPPTGER4
SCHEMBL16620129 0.83 PDE5A (0.38) CETPPTGER4
SCHEMBL18017381 0.82 PTGER4 (0.42) MEN1KMT2ARXRARXRBPTGER4
SCHEMBL16620041 0.82 ADRB1 (0.38) MEN1KMT2ARXRARXRBCETP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052099-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2019-08-21 EP disclosed
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed
EP-3052099-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS Merck Sharp & Dohme Corp. (US) 2016-08-10 EP disclosed
WO-2015050798-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2015-04-09 WO disclosed
WO-2015050798-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 MEN1 4791/4885KMT2A 4197/4885PDE4D 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.